Related Experiment Video
Updated: Jan 15, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.0K
Chimeric antigen receptor-based cell therapy for treating urological tumors
Huidi Tang1,2, Linpei Guo1,2, Wen Zhang1,2
1Institute of Medical Sciences, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Current Urology
|October 8, 2025
Summary
Chimeric antigen receptor (CAR) cell therapies show promise for urological cancers like kidney, bladder, and prostate cancer. Research is refining these immunotherapies to improve effectiveness and target tumor antigens more precisely.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Urological tumors present a significant global health challenge.
- Conventional therapies for urological malignancies are often insufficient.
- Cellular immunotherapies, including CAR-T, CAR-NK, and CAR-macrophage therapies, offer new treatment potential.
Purpose of the Study:
- To review the application of CAR cell therapy in renal cell carcinoma, bladder cancer, and prostate cancer.
- To analyze the current advantages and limitations of CAR cell therapies in urological tumors.
- To propose optimization strategies for CAR-T cell therapy in urological cancers.
Main Methods:
- Comprehensive literature review of CAR cell therapy applications in urological cancers.
- Analysis of existing data on CAR-T, CAR-NK, and CAR-macrophage therapies.
- Evaluation of current challenges and future directions for CAR-T cell optimization.
Main Results:
- CAR cell therapies demonstrate significant potential in treating major urological tumors.
- Ongoing research focuses on enhancing CAR-based strategies for precise tumor-associated antigen targeting.
- CAR-T, CAR-NK, and CAR-macrophage therapies are being refined for urological cancer treatment.
Conclusions:
- CAR cell therapy is a promising approach for urological cancers.
- Further optimization, particularly for CAR-T cells, is needed to overcome limitations.
- This review provides insights into future directions for developing effective urological cancer treatments.
